Organon (OGN)

Executive Summary

Organon & Co., spun off from Merck in 2021, is a global healthcare company focused on women's health, biosimilars, and established brands. With a portfolio of over 70 medicines, including leading contraceptive Nexplanon and fertility treatments, the company serves more than 140 markets. Organon leverages its commercial infrastructure to launch biosimilars and expand access to women's health products. Recent strategic partnerships, notably with Samsung Bioepis for biosimilars (e.g., SB17, a Stelara biosimilar), position it for growth in the $100B+ biosimilar market. However, near-term revenue growth is modest due to generic competition for legacy brands. The company's focus on underpenetrated women's health categories and emerging market expansion supports a steady outlook. Management's disciplined capital allocation and cost restructuring could drive margin expansion and shareholder returns.

Upcoming Catalysts (preview)

• Q4 2026FDA decision on SB17 (biosimilar to Stelara)65% success
• Q2 2026Phase 3 data for next-generation long-acting reversible contraceptive50% success